NCT02111499View on ClinicalTrials.gov

Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

May 31, 2014

Study Completion Date

June 30, 2014

Conditions
Psoriasis
Interventions
DRUG

LAS41004-IMP1

daily topical application

DRUG

LAS41004 IMP2

daily topical application

DRUG

LAS41004 IMP3

daily topical application

DRUG

LAS41004 IMP4

daily topical application

DRUG

LAS41004 IMP6

daily topical application

DRUG

LAS41004 IMP5

once daily, topical

Trial Locations (1)

22869

proDERM GmbH, Schenefeld

Sponsors

Lead Sponsor

Almirall, S.A.
All Listed Sponsors
collaborator

proDERM GmbH

INDUSTRY

lead

Almirall, S.A.

INDUSTRY